Anissa Leonard

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso et al. · Thorax · 2011 · 493 citations · Full text

Transient elastography in patients with cystic fibrosis

Renaud Menten, Anissa Leonard, Philippe Clapuyt et al. · Pediatric Radiology · 2010 · 83 citations

Medical Ultrasound, Medical Imaging, Diagnosis +6

Exophiala (Wangiella) dermatitidis and cystic fibrosis – Prevalence and risk factors

Patrick Lebecque, Anissa Leonard, Daniel Tsung‐Ning Huang et al. · Medical Mycology · 2010 · 48 citations · Full text

Molecular Diagnostic Techniques, Antibiotics, Pathology +10

Airway Delivery of Low-Dose Miglustat Normalizes Nasal Potential Difference in F508del Cystic Fibrosis Mice

Bob Lubamba, Jean Lebacq, Patrick Lebecque et al. · American Journal of Respiratory and Critical Care Medicine · 2009 · 45 citations

A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference

Anissa Leonard, Patrick Lebecque, Jasper Dingemanse et al. · Journal of Cystic Fibrosis · 2012 · 41 citations

Medicine, Randomized Placebo-controlled Trial, Nasal Potential Difference +1